Table 2.
Clinic-pathological and treatmet data of the present sample
| Variable | |
|---|---|
| Evolution time | Mean: 5.92 months |
| Range: 1-44 months | |
| Signs and symptoms | Swelling: 51 (87.9%) |
| Pain: 35 (60.4%) | |
| Staging | Stage I or II: 5 (8.6%) |
| Stage III or IV: 53 (91.4%) | |
| Histological grade | Low grade: 4 (6.9%) |
| Moderate grade: 45 (77.7%) | |
| High grade: 9 (15.5%) | |
| Surgical margins | Free: 20 (60.6%) |
| Comitted: 13 (39.4%) | |
| Regional metastasis | Present: 10 (17.2%) |
| Absent: 48 (82.8%) | |
| Distant metastasis | Present: 5 (8.6%) |
| Absent: 53 (91.4%) | |
| Local recurrence | Present: 10 (20.4%) |
| Absent: 39 (79.6%) | |
| Treatment modalities | No: 9 (15.5%) |
| RxT + ST: 22 (37.9%) | |
| RxT: 13 (22.4%) | |
| ST: 9 (15.5%) | |
| RxT + ChT: 3 (5.2%) | |
| ST + RxT + ChT: 2 (3.4%) | |
| Follow up | Mean: 18.1 months |
| Range: 1-108 months | |
| Outcomes | NED: 6 (10.3%) |
| AWD: 14 (24.2%) | |
| DOD: 38 (65.5%) |
AWD: alive with disease; ChT: chemotherapy; DOD: Died of disease; NED: no evidence of disease; RxT: radiotherapy; ST: surgical treatment.